We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

KINAXO Expands Technology Platform and Secures Additional Venture Capital


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "KINAXO Expands Technology Platform and Secures Additional Venture Capital"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

KINAXO Biotechnologies GmbH is expanding its technology platform to include mass spectrometry. This will allow KINAXO to better serve the increasing demand of the pharmaceutical industry for chemical proteomics analyses.

The in-house mass spectrometry facility is supported by scientific advisors Jesper Olsen and Juergen Cox, two experts from the department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry in Martinsried. KINAXO's technical equipment comprises an ultra-sensitive LTQ Orbitrap mass spectrometer from Thermo Fisher Scientific.

New lead investor Mountain Partners AG and co-investor KfW provided venture capital to fund KINAXO's technology expansion. Seeding investor High-Tech Gruenderfonds as well as KINAXO's shareholders Max Planck Society, BioM AG, Axel Ullrich and Hellmut Kirchner also participated in this financing round.

Advertisement